A8081075 - CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511128-15-00

Acronym

A8081075

Enrollment

Registered

2024-05-24

Start date

2023-01-17

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed

Brief summary

AEs leading to permanent discontinuation of crizotinib, All SAEs

Interventions

DRUGXALKORI 200 mg hard capsules

DRUGXALKORI 250 mg hard capsules

DRUGCrizotinib 200 mg capsules

DRUGCrizotinib 250 mg capsules

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
AEs leading to permanent discontinuation of crizotinib, All SAEs	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026